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Breast and colorectal cancers, are common types of cancer, with over two million 
newly diagnosed cases annually worldwide. Cancer is a genetic disease and 
defects in DNA integrity restoring functions make a significant contribution to 
cancer risk. CHEK2 is a checkpoint kinase functioning as a regulator of cell cycle 
checkpoints, apoptosis, and DNA repair in response to DNA double-strand 
breaks. 
 
The aim of this study was to evaluate the role of CHEK2 in breast cancer 
predisposition in Finnish breast cancer families and in breast cancer risk at the 
population level. We were interested in the clinical and biological characteristics of 
the breast tumors associated with the CHEK2 germline mutations or aberrant 
CHEK2 protein expression and the effect on survival of patients with these 
CHEK2 defects. We also assessed the role of CHEK2 mutations, namely 
1100delC and I157T, in colorectal cancer susceptibility in Finland.  
 
A total of 1383 breast cancer cases and 1885 healthy controls were screened for 
the CHEK2 variant I157T. Seventy-seven carriers of I157T were identified among 
1035 breast cancer cases unselected for family history of breast cancer (7.4%) 
and 100 carriers among 1885 healthy controls (5.3%). Altogether, CHEK2 I157T 
is associated with breast cancer risk, conferring a 1.4-fold risk to variant carriers. 
Immunohistochemical studies showed that CHEK2 I157T, unlike 1100delC, does 
not affect protein expression in breast tumors. The features of CHEK2 I157T were 
compared with wild-type CHEK2 in functional studies, and the CHEK2 I157T 
mutation was found not to affect CHEK2 stability or activation in response to 
ionizing radiation. CHEK2 I157T is defective in substrate binding, and we were 
able to show that CHEK2 I157T can dimerize with wt CHEK2, which may lead to a 
decreased number of functional CHEK2 in a cell.  
 
Clinical and biological characteristics of the breast tumors associated with CHEK2 






unselected breast cancer cases, respectively. One-fifth of breast tumors showed 
loss or reduction in CHEK2 immunostaining. Generally, the tumors from 1100delC 
carriers or those with aberrant expression were similar to noncarrier tumors or 
tumors with normal expression, respectively. Tumors with reduced CHEK2 
expression were, however, larger than normally staining ones, and the most 
aberrantly staining tumors were more often estrogen receptor (ER)-positive. 
Tumors from CHEK2 1100delC carriers were more often of higher grade than 
tumors from noncarriers and they also tend to be ER-positive more often. 
 
Contribution of CHEK2 1100delC to colorectal cancer risk and to the hereditary 
breast and colorectal cancer (HBCC) phenotype was studied in a set of 662 CRC 
patients unselected for family history and in 507 familial breast cancer cases, 
respectively. 2.6% of colorectal cancer (CRC) cases (17/662) carried 1100delC, 
which is not significantly higher than the geographically adjusted population 
frequency of 1.9%. Neither was the frequency of 1100delC higher in HBCC 
families than in breast cancer families. Our results suggest that CHEK2 1100delC 
may not be a susceptibility allele for CRC, although a small effect cannot be 
excluded. The role of CHEK2 missense variant I157T was also studied for 
colorectal cancer susceptibility and for association with clinical characteristics and 
family history of cancer. A population-based series of 1042 CRC cases was 
screened for CHEK2 I157T and a significantly higher frequency of I157T was 
observed among both familial (10.4%) and sporadic (7.4%) CRC cases: 7.8% in 
all cases combined vs. 5.3% in population controls. Association of I157T with 
familial CRC has not been studied previously. CHEK2 I157T seems to be a 
susceptibility allele for both familial and sporadic CRC, conferring a 1.5-fold risk 
for carriers of this variant. Furthermore, we observed a higher frequency of the 
variant among cases with multiple primary tumors or a family history of cancer, 
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Breast and colorectal cancers, both belong to the most common types of cancer. 
Cancer is a genetic disease, and in a significant number of cases the 
susceptibility to cancer is inherited. Mutations in high-penetrance susceptibility 
genes are rare at the population level, but confer a high risk for cancer and result 
in familial clustering of cancer cases. Lower penetrance susceptibility genes are, 
however, more common in the population and may contribute to cancer risk 
through interactions with other susceptibility genes and environmental factors. 
The effect of low-penetrance susceptibility genes may be great at the population 
level, but the prediction of an individual’s cancer risk is challenging if even 
possible. Information on cancer susceptibility alleles is increasing rapidly, and in 
the future it may become possible that information on several genetic factors and 
their interactions is utilized such that it is applicable at the individual level in 
clinical management of cancer. 
 
Our DNA is continuously challenged by situations where the DNA strands may 
break. Cells have developed a refined machinery to assure the integrity of DNA, 
and defects in this network of protein interactions may eventually result in cancer. 
One of the key players in DNA double-strand break (DSB) responses is CHEK2, a 
checkpoint kinase functioning as a regulator of cell cycle checkpoints, apoptosis, 
and DNA repair. This study focuses on the role of CHEK2 and its variants in 
breast and colorectal cancer susceptibility, and further, on the clinical and 






2 Review of the literature 
2.1 Cancer as a genetic disease 
Cancer is one of the most common causes of death in the developed world. One-
third of people will be diagnosed with cancer during their lifetime, and the 
diagnosis will touch most of us, either personally or via a loved one. Cancer is 
generally thought of being a disease of genes (Vogelstein and Kinzler, 2002). 
Cancer is characterized by several acquired qualities that differentiate cancerous 
tissue and cells from normal ones (Hanahan and Weinberg, 2000). Cancer cells 
can proliferate in the absence of growth signals, and they are insensitive to anti-
growth stimuli. Cancer cells can, furthermore, evade apoptosis, and they have 
limitless replicative potential – they can live forever. All tissues require oxygen and 
nutrients, and in order to grow a tumor needs to develop angiogenic ability 
(Hanahan and Folkman, 1996). These capacities enable cancer cells to invade 
other tissues and form metastases, which in the majority of cases is the cause of 
cancer death. Cancers arise as a result of genetic changes that promote the 
above-mentioned qualities mentioned accumulating over time. Genes that have 
been implicated in tumorigenesis are traditionally classified as oncogenes and 
tumor suppressor genes. Oncogenes are an altered form of cellular proto-
oncogenes that function in regulation of the cell cycle, cell division, and 
differentiation (Vogelstein and Kinzler, 2002). When appropriately activated by a 
mutation, a proto-oncogene becomes an oncogene and stimulates uncontrolled 
growth. At the cellular level, oncogenes are dominant, meaning that only one copy 
of the genes needs to be altered to promote oncogenesis. Tumor suppressors, as 
the name indicates, function in preventing inappropriate growth.  
Several rare hereditary cancer syndromes have been identified to date. The great 
majority of these are caused by a mutation in a tumor suppressor gene e.g. 
mutation in VHL in von Hippel-Lindau syndrome, in LKB1 in Peutz-Jeghers 
syndrome, and in PTEN in Cowden syndrome (Latif et al., 1993; Liaw et al., 1997; 
Hemminki et al., 1998). Because of the dominance at the celluar level, activated 






rarely inherited. The oncogenes involved in hereditary cancers include RET in 
thyroid cancer, CDK4 in cutaneous melanoma, and MET in papillary renal cell 
carcinoma (Mulligan et al., 1993; Zuo et al., 1996; Schmidt et al., 1997). 
2.1.1 Tumor suppressor genetics 
Over thirty years ago Knudson proposed his famous two-hit hypothesis 
suggesting that both alleles of a tumor suppressor gene need to be inactivated to 
promote tumorigenesis (Knudson, 1971; Knudson, 2001). Three different types of 
tumor suppressors are classically described: gatekeepers, caretakers, and 
landscapers (Kinzler and Vogelstein, 1997; Kinzler and Vogelstein, 1998). 
Gatekeepers are characterized by functions that directly inhibit cellular growth or 
promote death by apoptosis. These are the most classical tumor suppressors, like 
the RB gene in retinoblastoma, as described in Knudson’s original work 
(Knudson, 1971). Caretaker genes are usually involved in the control of genomic 
integrity and inactivation of a caretaker may not initiate tumor formation in itself, 
but could promote transformation by making the cell genetically unstable and 
therefore more prone to other mutations. Typically, genes involved in DNA repair 
belong to caretakers such as the breast cancer susceptibility genes BRCA1 and 
BRCA2. Landscapers play an indirect role in tumorigenesis by creating an 
abnormal microenvironment promoting tumorigenesis, which is known to happen 
in certain polyposis syndromes of the colon. 
 
Classically, the mechanism of tumorigenesis in association with tumor suppressor 
genes in inherited cancers involves the loss of the wild-type (wt) allele by loss of 
heterozygosity (LOH), often caused by a loss of a whole chromosome or a 
chromosome arm. Mutation of one allele may also result in reduction of gene 
product dosage, a phenomenon called haploinsufficiency. Tumor suppressor 
mutations can, however, have qualitative differences and function by a dominant 
negative mode of action whereby the wt protein is prevented from carrying out its 
function by binding to the mutant protein, or the mutation can result in the gain of 






different effect on function depending on the type of the mutation itself, tissue 
type, and environmental factors (Payne and Kemp, 2005). Several tumor 
suppressors have been shown to function through haploinsufficiency, e.g. p27kip1 
(Fero et al., 1998), p53 (Venkatachalam et al., 1998), and TGFβ1 (Tang et al., 
1998) even though their principal method of function may be the traditional two-hit 
mechanism. 
2.2 Breast cancer 
2.2.1 Epidemiology of breast cancer 
Breast cancer is the most common type of cancer in women worldwide, with an 
estimated 1.15 million new cases in 2002 (23% of all cancers in women). There 
are 4.4 million women living with breast cancer globally, nearly 17000 in Finland 
alone (diagnosis within 5 years); breast cancer is the most prevalent cancer in the 
world because of its high incidence and relatively good prognosis (Parkin et al., 
2005). In Finland, over 4000 women were diagnosed with breast cancer in 2006 
(estimate based on 2004 incidence; Finnish Cancer Registry, www.cancerregistry.fi ). 
The majority of breast cancer cases are sporadic, while up to 10% of breast 
cancers are hereditary in nature and caused by dominantly inherited mutations 
(McPherson et al., 2000; Dapic et al., 2005; Lacroix and Leclercq, 2005). The 
major breast cancer predisposition genes are BRCA1 and BRCA2, which confer a 
very high lifetime risk of breast and ovarian malignancy (Miki et al., 1994; Wooster 
et al., 1995; Antoniou et al., 2003). Breast cancer is also a characteristic in rare 
hereditary cancer syndromes, such as Li-Fraumeni syndrome (mutated gene p53) 
and Cowden syndrome (PTEN), appearing also in Peutz-Jeghers syndrome 
(LKB1).  
Familial aggregation of breast cancer, when BRCA1 and BRCA2 mutations have 
been ruled out, may be a result of several low-penetrance genes with a 
multiplicative effect (Antoniou et al., 2002). Moreover, results from a population-
based study and modeling of breast cancer risk indicate that breast cancer 






variants (Pharoah et al., 2002). Breast cancer risk can be described as a 
continuum between environmental factors and high-penetrance susceptibility 
genes, where several low-penetrance genetic variants interact with each other 
and the environment (Balmain et al., 2003). Altogether, it is estimated that about 
30% of breast cancer is estimated to be caused by heritable factors (Lichtenstein 
et al., 2000).Family history remains the strongest risk factor, while other known 
risk factors for breast cancer include certain reproductive factors, body size, 
exogenous hormones, ionizing radiation, physical inactivity, and possibly diet 
(McPherson et al., 2000; Hulka and Moorman, 2001; Coyle, 2004; Parkin et al., 
2005). The incidence rate has been constantly growing, and the greatest increase 
in incidence has been seen in areas where the incidence was formerly low, e.g. in 
China and other Eastern Asian countries. In addition, the development of effective 
screening programs in affluent countries has contributed to increased detection of 
early invasive breast tumors, which may otherwise have been diagnosed later or 
not at all (Parkin et al., 2005). The estimate for the number of new cases 
worldwide in 2010 is 1.4-1.5 million (Parkin et al., 2005). Breast cancer also 
occurs in males, but it is very rare, the greatest risk factor for male breast cancer 
being a mutation in BRCA2 (Weiss et al., 2005). 
2.2.2 Clinicopathologic features of breast cancer 
Practically all breast tumors are carcinomas, with the tumor arising from epithelial 
cells (Berg and Hutter, 1995). Breast tumors are typically adenocarcinomas; the 
malignancy originates in the glandular epithelia. The most common histological 
types of breast carcinoma are infiltrating ductal carcinoma (~70%), lobular 
carcinoma (~6%), and medullary carcinoma (~3%). Breast carcinomas are 
classified according to the TNM staging system (T, extent of the primary tumor; N, 
absence or presence of the disease in the lymph nodes; M, absence or presence 
of distant metastasis). The numerical staging helps in planning treatment and 
evaluating treatment results; as it also indicates prognosis. The TNM staging 
system is continuously being updated and improved by the International Union 






estrogen receptor (ER) and progesterone receptor (PR) in breast tumors, is 
considered to be an indicator of good response to hormone treatment and good 
prognosis (reviewed in Duffy, 2005).  
2.3 Colorectal cancer 
An estimated one million new colorectal cancer (CRC) cases occurred worldwide 
in 2002 (Parkin et al., 2005). In Finland, colorectal cancer is the second most 
common cancer in women (after breast cancer) and the third most common 
cancer in men (after prostate and lung cancers) (Finnish Cancer Registry, 
www.cancerregistry.fi). The great majority of colorectal cancer cases are sporadic, 
indicating that cancer occurs in individuals without a family history of cancer. 
Consistent evidence suggests that certain lifestyle-associated factors, such as 
physical inactivity, obesity, excess alcohol use, and meat consumption, are linked 
to an increased risk of colorectal cancer (Giovannucci, 2002). One of the most 
important risk factors for colorectal cancer is, however, family history of CRC, 
indicating that inherited susceptibility plays a significant role in colorectal cancer 
development; 35% of colorectal cancers are likely attributable to hereditary factors 
(Lichtenstein et al., 2000; Slattery et al., 2003).   
2.3.1 Genetic risk factors for colorectal cancer 
Familial colorectal cancers such as familial adenomatous polyposis (FAP) and 
Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer, 
HNPCC), account for about 5% of the incidence of CRC (Burt and Neklason, 
2005). These autosomally dominantly inherited cancer syndromes are, in the 
majority of cases, caused by mutations in the APC gene and DNA mismatch 
repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2), respectively, as reviewed 
in (Peltomaki, 2005; Lipton and Tomlinson, 2006). There is, however, evidence 
that approximately 20-30% of colorectal cancer have a heredity component 
(Lynch and de la Chapelle, 2003, Bodmer, 2006) and that a relative with CRC 






2001). The first identified genetic variant in CRC that doesn not result in familial 
clustering of the disease but predisposes to CRC was missense variant I1307K in 
the APC gene among Ashkenazi Jewish CRC families (Laken et al., 1997). This 
finding was subsequently confirmed by Frayling et al., (1998). They also identified 
another missense variant in APC, E1317Q, which associated with adenoma and 
early onset CRC cases among patients of Ashkenazi descent. Further 
confirmation of these results was presented by Lamlum et al. (2000). These 
findings have led to the so-called rare variant hypothesis (Frayling et al., 1998; 
Bodmer, 1999), which suggests that rare dominantly acting variants conferring a 
moderate risk may together define the inherited susceptibility to multifactorial 
diseases like cancer.  
 
The association between colorectal cancer and several polymorphisms in genes 
involved in metabolic pathways, methylation, immune responses, and iron 
metabolism as well as colonic microenvironment-modifying genes, and 
oncogenes and tumor suppressor genes have been studied in meta-analyses (de 
Jong et al., 2002; Chen et al., 2005; Hubner and Houlston, 2007). Polymorphisms 
in several genes, including GSTT1, NAT2, HRAS1, and ALDH2 have been 
associated with moderately increased risk for colorectal cancer (de Jong et al., 
2002; Chen et al., 2005). A common functional polymorphism in methyl 
tetrahydrofolate reductase (MTHFR), 677C>T (A222V), has been associated with 
decreased risk of colorectal cancer (de Jong et al., 2002; Hubner and Houlston, 
2007; Huang et al., 2007), as has 1298A>C (E429A) (Huang et al., 2007). 
MTHFR may represent a low-penetrance susceptibility gene for CRC, and the 
polymorphisms would specifically protect against a colorectal adenoma 
developing into cancer since no association with colorectal adenoma was 
observed for either of the variants (Huang et al., 2007). There is also convincing 
evidence that a tumor suppressor, transforming growth factor β receptor 1 
(TGFβR1) polymorphism, a stretch of six alanines instead of the more common 
nine in the first coding exon, would increase risk of CRC with OR of 1.24, 95% 






2.4 DNA double-strand break (DSB) responses 
Humans, as well as other higher organisms, have evolved complicated signaling 
pathways for DNA damage repair and promotion of genomic stability. DNA in 
every cell is exposed to damaging agents that may result in DNA breakage. DNA 
damage may be caused by ultraviolet (UV) radiation, mutagenic chemicals, 
ionizing radiation (IR), cell oxidative metabolism, or mechanical stress on 
chromosomes, but may also occur normally during the processes of DNA 
replication, meiotic exchange, and V(D)J recombination of the immunoglobulin 
genes. The most serious type of DNA damage is DNA double-strand break (DSB). 
In DNA DSB, both strands are broken at corresponding sites and the ends of the 
chromatin may become physically dissociated from each other, which may in turn 
result in inappropriate recombination with other genomic sites. In addition, DNA 
DSBs are generated on purpose in the initiation of recombination in meiosis, and 
it also occurs in developmentally regulated rearrangements such as 
immunoglobulin class switch and V(D)J  recombination. Generation of DNA DSBs 
may result in induction of mutations and chromosomal translocations (Lengauer et 
al., 1998; Richardson and Jasin, 2000; Ferguson and Alt, 2001; Khanna and 
Jackson, 2001). In a normally functioning cell, DNA DSBs initiate a 
signaltransduction cascade. DNA damage is first detected by sensors, which then 
activate the transducers (protein kinases). The kinase cascade amplifies the 
signal and targets it to downstream effectors. Defects in cellular processes that 
respond to DNA DSBs are fundamental to the etiology of most cancers (Khanna 
and Jackson, 2001)). DNA DSBs may induce gene mutations, translocations and 
cell transformations, thus contributing to oncogenesis (for review, see 
Hoeijmakers, 2001). Many of the proteins belonging to DNA DSB response 
pathways are associated with cancer (Thompson and Schild, 2002). The key 
breast cancer susceptibility gene products; BRCA1, BRCA2, and TP53, are all 
involved in DNA DSB repair and chromosomal stability (Jasin, 2002; Valerie and 








There are two separate mechanisms of DNA DSB repair: the homologous 
recombination repair (HRR) pathway and the nonhomologous end-joining (NHEJ) 
pathway (Hoeijmakers, 2001; Valerie and Povirk, 2003). The choice of pathway 
may be determined by whether the DNA region has already replicated and the 
precise nature of the break. HRR is usually preferred when the identical DNA 
copy is available since NHEJ is more prone to errors. NHEJ functions at all stages 
of the cell cycle, but plays the predominant role in both the G1 phase and the S 
phase regions of DNA that have not yet replicated, while HRR functions primarily 
in repairing DSBs arising in S or G2 phase chromatid regions that have replicated 
(Rothkamm et al., 2003). 
 
The importance of DNA DSB responses is highlighted by the fact that numerous 
cancer susceptibility syndromes are caused by defects in genes involved in DNA 
DSB responses (Hoeijmakers, 2001; Khanna and Jackson, 2001; Kastan and 
Bartek, 2004; O'Driscoll and Jeggo, 2006). These syndromes are presented in 
Table 1. 
Table 1. Cancer susceptibility linked to defects in genes involved in DNA DSB 
responses. 
Syndrome Gene Cancer Susceptibility Other features
Ataxia telangiectasia (AT) ATM
leukemia, lymphoma (stomach, 
liver, pancreas, ovary, breast, 
salivary gland)
cerebellar ataxia, telangiectases, 
immunological defects
AT-Like Disorder (ATLD) MRE11A like AT milder clinical course than in AT
Nijmegen Breakage Syndrome 
(NBS) NBS leukemia, lymphoma
microcephaly, growth retardation, 
immunodeficiency
Werner Syndrome (WRN) WRN (RECQL2)
sarcoma, (general susceptibility to 
malignancies)
scleroderma-like skin changes, cataract, 
subcutaneous calcification, premature 
arteriosclerosis, diabetes mellitus, a wizened 
and prematurely aged face
Bloom's Syndrome (BLM) BLM (RECQL3)
general susceptibility to 
malignancies
pre- and postnatal growth deficiency; sun-




skin atrophy and 
dyspigmentation,telangiectasia, juvenile 
cataract, congenital bone defects, hair growth 
disturbances, hypogonadism
Li-Fraumeni Syndrome TP53
soft tissue sarcomas and 
osteosarcomas, breast, brain, 
leukemia, adrenocortex
typically early onset of tumors, multiple 
tumors within an individual
Hereditary Breast and Ovarian 
Cancer (HBOC) BRCA1 breast, ovarian
BRCA2
breast (also in males), ovarian, 






2.5 Cell cycle checkpoint kinase 2 (CHEK2) 
Cell cycle checkpoint kinase 2 (CHEK2) has an important role in regulating 
cellular responses to DSBs. It participates in controlling the cell cycle at several 
checkpoints, committing to apoptosis, and regulating DNA DSB repair; see Figure 















Figure 1 Simplified presentation of the CHEK2 pathway: three major functions of 
CHEK2 and its important interaction molecules. 
2.5.1 CHEK2 gene and protein structure 
The CHEK2 gene (ENSG00000183765, OMIM +604373) consists of 14 protein 
coding exons located on chromosome 22q12.1. According to current knowledge, 
CHEK2 has one untranslated exon at the 5’ end of the gene located 






have given rise to several pseudogenes that are present in several chromosomes, 
which has complicated the research of these CHEK2 exons. 
 
The CHEK2 gene encodes a protein product of 543 amino acids (aa). The CHEK2 
protein has three separate well-conserved protein domains: the N-terminal 
regulatory SQ/TQ cluster domain (SCD), the forkhead-associated (FHA) domain 
responsible for protein-protein interactions, and a large C-terminal kinase domain 
(Matsuoka et al., 1998). The SCD consists of five serine-glutamine (SQ) and two 
threonine-glutamine (TQ) pairs in the aminoterminus (aa residues 19-69). SCD 
has an important role in the (auto)activation and regulation of CHEK2 since this 
domain is a target of several phosphorylations. The FHA domain (aa residues 
112-175) is responsible for phosphorylation-dependent protein-protein interactions 
of CHEK2 and defining the substrate specificity of CHEK2 (Durocher and 
Jackson, 2002). The kinase domain covers almost half of the whole protein (aa 
residues 220-486), defining CHEK2 as a serine-threonine kinase. The kinase 
domain also has two important (auto)phosphorylation sites (Thr 383 and Thr387), 
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Figure 2 Structure of CHEK2 protein with its domains and major phosphorylation sites. 
2.5.2 CHEK2 activation and function in DSB responses 
CHEK2 is a serine-threonine kinase playing a central role in cell cycle regulation, 
apoptosis, and DNA repair mechanisms. CHEK2 is activated through a series of 
phosphorylations in response to DNA DSBs. Upon IR –induced DSBs, ATM is the 






Thr68 in the SCD (Ahn et al., 2000; Matsuoka et al., 2000; Melchionna et al., 
2000). When DSBs are caused by UV irradiation or hydroxyurea treatments, 
CHEK2 is likely to be activated by ATR kinase (ATM and Rad3 –related) instead 
(Tominaga et al., 1999; Matsuoka et al., 2000). After the initiating phosphorylation, 
dimerization of CHEK2 takes place through a FHA domain and a Thr68-
phosphorylated SCD (Ahn and Prives, 2002; Ahn et al., 2002; Xu et al., 2002). 
CHEK2 becomes fully activated by a series of autophosphorylations, including 
phosphorylation of Thr383 and Thr387 in the activation loop and Ser516 C-
terminal to the kinase domain (Lee and Chung, 2001; Wu and Chen, 2003). 
CHEK2 dimerization upon the initial phosphorylation may promote the trans-
phosphorylation in the FHA domain and the subsequent release of active CHEK2 
monomers (Ahn et al., 2002; Xu et al., 2002). There are several equally important 
steps in the activation of CHEK2, and it has been suggested that the CHEK2 
pathway would become fully activated only when number of DNA DSBs is 
sufficiently high and that smaller injuries would be repaired without inducing cell 
cycle arrest (Buscemi et al., 2004), as has been observed to happen in yeast 
(Leroy et al., 2001). 
 
CHEK2 relays the message of DNA damage forward to effectors that function in 
several pathways leading to cell cycle arrest in the G1/S, S, and G2/M phases, 
activation of DNA repair, and apoptosis. The most important and studied 
substrates of CHEK2 phosphorylation are p53, BRCA1, and CDC25 
phosphatases. CDC25A and CDC25C phosphatases are important cell cycle 
checkpoint regulators that are in turn regulated by CHEK2; CDC25 phosphatases 
are reviewed in Donzelli and Draetta (2003). Phosphorylation of Ser123 in 
CDC25A directs it to proteasome-mediated degradation (Falck et al., 2001b) and 
prevents CDC25A from activating CDK2 and thus the cell cycle progression from 
G1 to S. CHEK2 also regulates cell cycle progression in G2/M, where 
phosphorylation of CDC25C on Ser216 leads to binding of CDC25C by 14-3-3 
proteins, thus preventing CDC25C from activating CDC2, a kinase that regulates 







Phosphorylation of p53 on Ser20 by CHEK2 stabilizes it, and p53 in turn regulates 
downstream targets controlling the cell cycle checkpoints, apoptosis, and DNA 
repair (Chehab et al., 1999; Chehab et al., 2000; Hirao et al., 2000; Shieh et al., 
2000). In nondamaged cells, p53 is quickly directed to proteasome-mediated 
degradation by binding of Mdm2 (Haupt et al., 1997; Kubbutat et al., 1997; 
Midgley and Lane, 1997). The number of CHEK2-p53 complexes has been 
observed to increase in response to DNA damage (Falck et al., 2001a). There are 
also reports that question the role of CHEK2 in p53 regulation (Jack et al., 2002; 
Ahn et al., 2003; Jallepalli et al., 2003). This controversy is understandable since 
the regulatory networks are complex and there is variation in response to different 
kinds and different amounts of cellular stress. There might also be differences in 
study designs and in cell or tissue types investigated. CHEK2 is considered a 
modifier or amplifier in several responses, and not be the primary kinase in the 
actions (Bartek and Lukas, 2003). 
 
BRCA1 has a central role in breast cancer susceptibility, but its precise 
mechanism of function in DNA repair remains somewhat unclear, although well 
established (Zhang and Powell, 2005). CHEK2 phosphorylates BRCA1 on 
Ser988, and it leads to release of BRCA1 from CHEK2 itself (Lee et al., 2000) and 
promotion of less error-prone homologous recombination in DNA repair (Zhang et 
al., 2004). 
 
Promyelocytic leukemia (PML) protein has been named after the PML gene, 
which is found to be translocated in the majority of acute promyelocytic leukemias 
(APLs) (de The et al., 1991). CHEK2 phosphorylates PML protein in response to 
DNA DSBs on Ser117 both in vivo and in vitro, and this phosphorylation by 
CHEK2 is also a prerequisite for the colocalization of PML and CHEK2 in nuclear 
bodies and their separation after IR (Yang et al., 2002). Thus, CHEK2 has an 
important role in regulating PML-mediated apoptosis after IR. Furthermore, PML 
is involved in p53-mediated DNA integrity-restoring functions (Bernardi et al., 







Transcription factor E2F1 functions in controlling apoptosis, DNA repair, and 
proliferation (DeGregori and Johnson, 2006). CHEK2 phosphorylates E2F1 on 
Ser364 in vivo and in vitro, which leads to stabilization and transcriptional 
activation of E2F1 and to changes in E2F1 nuclear localization (Stevens et al., 
2003). This activation of E2F1 provides a signal for E2F1-mediated, p53-
independent apoptosis and cell cycle arrest (Stevens et al., 2003; Rogoff et al., 
2004). Activation of E2F1 may create an amplifying effect on DNA damage 
signaling since, as a transcription factor, E2F1 has been shown to induce CHEK2 
expression (Rogoff et al., 2004). The targets of CHEK2 phosphorylation presented 
here are not the only CHEK2 substrates identified to date, but represent the ones 
most studied and perhaps also the most important.  
 
CHEK2 is a predominantly nuclear protein expressed throughout the cell cycle 
(Matsuoka et al., 1998; Lukas et al., 2001). CHEK2 is also abundant in quiescent 
cells and is detectable regardless of the differentiation or proliferation state of cells 
(Lukas et al., 2001). CHEK2 is also a relatively stable protein with a half-life of 
over two hours (Lee et al., 2001) and the level of CHEK2 has been shown to 
remain practically unchanged even for six hours (Lukas et al., 2001). The nuclear 
localization is unaffected by DSB-induced activation (Tominaga et al., 1999). 
Activation is observed to be restricted to the DNA DSB sites, but once activated 
CHEK2 mediates the message of DNA damage throughout the nucleus (Lukas et 
al., 2003). 
 
CHEK2 functions have been studied by producing Chk2 (CHEK2 homolog) knock-
out mice. Chk2 is not an essential gene in mice since Chk2-/- mice are viable 
(Hirao et al., 2002). These knock-out mice appear normal, but they are 
significantly more resistant to ionizing radiation than wt mice (Takai et al., 2002). 
Cells lacking Chk2 are defective in p53 stabilization, induction of p53-dependent 
transcripts, maintaining G2 arrest, and resisting p53-mediated apoptosis in 
response to IR (Hirao et al., 2000; Hirao et al., 2002; Takai et al., 2002). A study 
in human cells with antisense inhibition of CHEK2 supports the model in which 






the age of one year, Chk2-/- mice did not develop tumors spontaneously, but it has 
been speculated that tumors are too rare to detect or that they may take a longer 
time to develop (Hirao et al., 2002). Chk2-/- mice did, however, develop more 
tumors and at an earlier age when exposed to chemical carcinogen compared 
with wt mice (Hirao et al., 2002). 
2.5.3 CHEK2 becomes a cancer susceptibility gene 
The majority of LFS patients have a germline mutation in p53 (Malkin et al., 1990; 
Srivastava et al., 1990). The characteristics of LFS include a predisposition for 
several tumors: breast cancer, brain tumors, leukemia, early onset sarcomas, and 
adenocortical carcinoma (Li and Fraumeni, 1969), as reviewed in Varley et al. 
(1997) and Varley (2003). CHEK2 was first discovered as a tumor suppressor 
candidate by Bell et al. in 1999, when they identified germline mutations in 
CHEK2 in patients with Li-Fraumeni syndrome (LFS) or Li-Fraumeni-like 
syndrome (LFL) who did not have a mutation in p53. Further studies on CHEK2 in 
LFS, LFL, and breast cancer families with phenotypic features of LFS revealed 
two carriers of CHEK2 1100delC, and both were breast cancer patients with a 
family history only suggestive of LFS (Vahteristo et al., 2001b). 
 
This observation and linkage studies on breast cancer families led to the 
identification of CHEK2 c.1100delC as a breast cancer susceptibility allele by two 
research groups almost simultaneously (Meijers-Heijboer et al., 2002; Vahteristo 
et al., 2002). CHEK2 c.1100delC (called 1100delC) was found to associate with 
hereditary nonBRCA1/2 breast cancer with similar frequencies in both studies, 
4.2% and 5.5% vs. 1.1% and 1.4% in population controls, respectively (Meijers-
Heijboer et al., 2002; Vahteristo et al., 2002). The frequency of 1100delC was not 
significantly elevated among breast cancer patients unselected for family history 
in these studies. Later, a large study involving 10860 cases and 9065 controls 
proved that there is, in fact, an association between CHEK2 1100delC and 
unselected breast cancer, with frequencies of 1.9% and 0.7% in cases and 






(CHEK2 Breast Cancer Case-Control Consortium, 2004). Thus CHEK2 1100delC 
doubles the risk for breast cancer. A very recent report with a large study group 
conclude that CHEK2 1100delC is associated with a threefold risk of breast 
cancer in women in the general population and may also increase the risk of other 
cancers (Weischer et al., 2007). 
2.5.4 Cancer-associated mutations in CHEK2 
2.5.4.1 CHEK2 1100delC 
The CHEK2 1100delC mutation resides at the beginning of the tenth protein 
coding exon of CHEK2. Deletion of one cytosine residue results in a frameshift 
and finally a stop codon at aa position 381, in the middle of the kinase domain. 
Studies have shown that either the truncated protein product is not expressed or 
the expression is dramatically lowered (Dong et al., 2003; Jekimovs et al., 2005; 
Bahassi et al., 2007). Since 2002, when CHEK2 1100delC became acknowledged 
as the first low-penetrance breast cancer susceptibility allele (Meijers-Heijboer et 
al., 2002; Vahteristo et al., 2002), this mutation has been under extensive 
investigation.  
 
Interestingly, CHEK2 1100delC seems to not be present in all populations, but the 
frequency of 1100delC varies from 0.0% to 1.4% in the general population in 
studied populations, being highest in Finland and the Netherlands; see Table 2 
(Meijers-Heijboer et al., 2002; Vahteristo et al., 2002). CHEK2 1100delC 
predisposes to familial breast cancer as well as to breast cancer in general 
(CHEK2 Breast Cancer Case-Control Consortium, 2004). Prevalence of 1100delC 
among male breast cancer patients seems, however, to be similar to that of the 
general population, Table 2, although first suggested otherwise (Meijers-Heijboer 
et al., 2002). CHEK2 1100delC has also been studied among breast cancer 
families with BRCA1 or BRCA2 mutation, but none or very few 1100delC carriers 







Very recently, a CHEK2 1100delC knock-in mouse was generated for 
investigating the effects of 1100delC mutation in cells. Embryonic cells from these 
mice show an increased number of DSBs and polyploidy, and their cell cycle 
profile is altered (Bahassi et al., 2007). Furthermore, these authors were able to 
show a dose-dependent relationship between Chk2 mRNA and CHEK2 1100delC 
status. Jekimovs et al. (2005) observed this same phenomenon in humans, when 
comparing 1100delC carriers to wt CHEK2. Interestingly, Bernstein et al. (2006) 
noted an increased risk for breast cancer in CHEK2 1100delC carrier women 
exposed to radiation (chest X-rays). These data support the biological relevance 
of functional CHEK2 in response to DNA DSBs and breast carcinogenesis. 
Table 2. Prevalence of CHEK2 1100delC among breast cancer cases unselected 
for family history, familial cases (both nonBRCA1/2 and BRCA1/2), and 
male breast cancer cases in different populations. 
Study group % +ve/Total % +ve/Total OR 95% CI p Reference
Unselected cases
Australian 0.7 10/1474 0.1 1/736 5.0 0.6-39.3 0.09 CHEK2 Consortium, 2004
British (East Anglia) 1.2 35/2886 0.5 20/3749 2.3 1.3-4.0 0.002 CHEK2 Consortium, 2004
British 1.3 7/564 0.3 1/288 3.6 0.4-29.5 0.20 CHEK2 Consortium, 2004
Dutch 3.8 65/1706 1.6 3/184 2.4 0.7-7.7 0.13 CHEK2 Consortium, 2004
Dutch 3.3 35/1066 0.0 0/265 - - - CHEK2 Consortium, 2004
Finnish (Helsinki, Tampere) 2.0 21/1035 1.4 26/1885 1.5 0.8-2.7 0.18 Vahteristo et al., 2002
Finnish (Kuopio) 2.9 13/464 1.1 5/447 2.5 0.9-7.2 0.07 CHEK2 Consortium, 2004
German 0.3 2/601 0.2 1/650 2.2 0.2-24.0 0.52 CHEK2 Consortium, 2004
German 1.1 11/985 0.2 1/401 4.5 0.6-35.1 0.11 CHEK2 Consortium, 2004
Polish 0.5 11/2012 0.25 10/4000 2.2 0.9-5.2 0.1 Gorski et al., 2005
Russian 2.7 22/815 0.2 1/448 12.4 1.7-92.3 0.0016 Chekmariova et al., 2006
Spanish (Basque Country) 0.9 2/214 0.0 0/120 - - - Martinez-Bouzas et al., 2007
Swedish (postmenopausal) 1.3 20*/1510 0.6 8/1334 2.2  0.9-5.1 0.05 Einarsdottir et al., 2006
US (Washington, dg <45yrs) 1.2 6/505 0.4 2/458 2.7 0.6-13.7 0.20 Friedrichsen et al., 2004
US and Canadian 1.3 30/2311 0.2 1/496 6.7 2.4-18.7 0.20 Bernstein et al., 2006
Familial cases (BRCA1/2 neg)
British 5.7 12/211 1.0 8/810 6.0 2.4-15.0 0.000 Meijers-Heijboer et al., 2002
Dutch 4.9 11/226 1.4 9/644 3.6 1.5-8.8 0.003 Meijers-Heijboer et al., 2002
Finnish (Helsinki, Tampere) 5.5 28/505 1.4 26/1885 4.2 2.4-7.2 0.000 Vahteristo et al., 2002
German 1.6 8/516 0.5 6/1315 3.4 1.2-9.9 0.02 Dufault et al., 2004
Italian 0.1 1/696 0.0 0/334 - - - Caligo et al., 2004
Spanish 0.0 0/400 0.0 0/400 - - - Osorio et al., 2004
US and Canadian 2.3 6/264 0.6 1/166 3.8 0.5-32.1 0.18 Meijers-Heijboer et al., 2002
US (New York) 1.1 1/92 0.3 5/1665 3.6 0.4-31.6 0.21 Offit et al., 2003
Male breast cancer
British 0.0 0/79 0.5 20/3749 - - - Neuhausen et al., 2004
Finnish 1.8 2/114 1.4 26/1885 1.3 0.3-5.4 0.74 Syrjäkoski et al., 2004
Israeli 0.0 0/54 0.0 0/146 - - - Ohayon et al., 2004
US (Colorado, Idaho, Utah, Wyoming) 0.0 0/109 0.7 1/138 - - - Neuhausen et al., 2004
US (New York) 0.0 0/16 0.0 0/146 - - - Offit et al., 2003
BRCA1/2  mutation carriers
British 0.0 0/52 1.0 8/810 - - - Meijers-Heijboer et al., 2002
Dutch 0.7 1/141 1.4 9/644 - - - Meijers-Heijboer et al., 2002
Finnish 0.0 0/19 1.4 26/1885 - - - Vahteristo et al., 2002
Israeli 0.5 1/219 0.0 1/146 0.7 0.04-10.7 0.77 Ohayon et al., 2004
Italian 0.0 0/183 0.0 0/334 - - - Caligo et al., 2004
US and Canadian 0.0 0/122 0.6 1/166 - - - Meijers-Heijboer et al., 2002








2.5.4.2 CHEK2 I157T 
CHEK2 I157T was first described by Bell et al. in 1999 in a LFL family as an LFS 
mutation and subsequently also in a LFS family (Bell et al., 1999; Lee et al., 
2001). CHEK2 470T>C leads to aa substitution of isoleucine by threonine at 
position 157 in the FHA domain of CHEK2. The variant is commonly known as 
I157T even when referring to the change at a DNA level. The nature of this 
missense variant was studied, and the mutation was observed to deleteriously 
affect binding of CHEK2’s three notorious substrates p53, BRCA1, and CDC25A 
(Falck et al., 2001a; Falck et al., 2001b; Li et al., 2002), even though CHEK2 
I157T becomes normally activated after γ-radiation (Wu et al., 2001). CHEK2 
I157T has also been shown to impair the oligomerization and 
autophosphorylations of CHEK2 (Schwarz et al., 2003). CHEK2 I157T was 
identified in Finland in the screening of CHEK2 for mutations in LFS and breast 
cancer families (Allinen et al., 2001; Vahteristo et al., 2001b) and was also 
detected in normal controls. In this thesis, the contribution of this variant to cancer 
risk was further studied.  
2.5.4.3 CHEK2 IVS2+1G>A and a large deletion in CHEK2 
Variation in CHEK2 seems to be very population-specific, and several variants 
have been reported only in one population or in very few populations. One of 
these is a splice-site mutation CHEK2 IVS2+1G>A in intron two, which results in a 
4 bp insertion and a premature termination codon in exon 3 (154X). This variant 
was first described by Dong et al. (2003) in a prostate cancer case in the United 
States. Since this variant has a clear effect on CHEK2 protein function, it has 
been actively investigated. In all studies, the frequency of CHEK2 IVS2+1G>A 
has been very low in controls, 0.48% being the highest reported in a larger 
sample set of Polish origin (Cybulski et al., 2004a). These authors reported a 
significant association of CHEK2 IVS2+1G>A with both unselected and familial 
prostate cancer, and soon after, with breast, thyroid, and stomach cancers in 
Poland (Cybulski et al., 2004a; Cybulski et al., 2004b). A joint study with German 






observed a nonsignificantly higher number of IVS+1G>A carriers among breast 
cancer patients than among controls (Bogdanova et al., 2005). No difference in 
frequency of IVS2+1G>A was detected in screening of 516 German breast cancer 
families and 500 controls (two positive cases were identified in both groups) 
(Dufault et al., 2004). This mutation has also been screened in 345 Finnish 
familial breast cancer cases, but no mutation carriers were identified (Kilpivaara et 
al., unpublished). This mutation does not seem to exist in the Finnish population, 
or it is even rarer than in other studied populations, and thus, its contribution to 
breast cancer risk in Finland is unlikely. 
 
Until very recently, all reported mutations in CHEK2 have been point mutations or 
mutations involving only very few bases. Walsh et al. (2006) reported a large 
deletion (5.6 kb) in CHEK2 in two high-risk breast cancer families of 
Czechoslovakian ancestry. This deletion was found in eight patients with breast 
cancer (n=631, 1.3%) and in none of the 367 healthy controls in the Czech 
Republic and Slovakia (Walsh et al., 2006). Soon after, the Polish group defined 
the mutation to be a deletion of 5395 bp (exons 9 and 10) and they observed it in 
39/4454 unselected breast cancer cases (0.9%) and in 24/5496 controls (0.4%), 
p=0.009, OR=2.0, 95%CI=1.2-3.4 (Cybulski et al., 2006b). They also studied the 
prevalence among prostate cancer patients and identified the deletion in 15/1864 
unselected cases (0.8%) and 4/249 familial prostate cancer cases (1.6%), where 
association with familial prostate cancer was statistically significant (p=0.03, 
OR=3.7, 95% CI=1.3-10.8) (Cybulski et al., 2006a). This large genomic deletion in 
CHEK2 has thus far been identified only in patients of Slavic origin, and it seems 
to exhibit similar frequencies as IVS2+1G>A. This CHEK2 deletion is currently 
under investigation in Finland. 
2.5.4.4 Other germline variants in CHEK2 
Several rare variants in CHEK2 have been identified in cancer patients. Missense 
variant R145W with a deleterious effect on CHEK2 was first identified in a CRC 






2001). Friendrichsen et al. (2004) observed one mutation carrier among 506 
breast cancer cases and 459 controls in the USA, but no other observations of 
this mutation have been reported. This mutation is seemingly very rare, or 
restricted, like other CHEK2 variants, to certain populations. Unique cases, 
CHEK2 variants E161del (483delAGA), R117G, R137Q, R180H, have been 
observed in breast cancer families (Sodha et al., 2002a; Sodha et al., 2002b), and 
very recently, delE161 and R117G have been found to be pathogenic in 
bioinformatic as well as in biochemical studies (Sodha et al., 2006). Another 
missense variant with an unknown functional effect has been observed in Iceland. 
Variant T59K was detected in 8/1172 Icelandic cancer cases (breast, colorectal, 
stomach, ovarian), but in none of the 452 controls (Ingvarsson et al., 2002). This 
variant may represent a population-specific rare variant in CHEK2 since this is, to 
my knowledge, the only report of this variant. 
  
Two novel missense variants, S428F (1283C>T) and P85L (254C>T), were 
recently identified in an Ashkenazi Jewish population (Shaag et al., 2005). Variant 
P85L was found to be neutral, but variant S428F residing in the CHEK2 kinase 
domain abrogates the CHEK2 function and is associated with a twofold increase 
in breast cancer risk among Ashkenazi Jews, 2.88% (47/1632) carriers in cases 
and 1.37% (23/1673) in controls (p=0.004, OR=2.13, 95% CI=1.26-3.69) (Shaag 
et al., 2005). 
 
The effect of common variation in CHEK2 on breast cancer risk and survival has 
also been evaluated. Kuschel et al. (2003) studied two polymorphisms in CHEK2 
in British breast cancer patients, but observed no risk associated with the 
variation. The same material was used in another study, where the effect of two 
CHEK2 SNPs on breast cancer patients’ survival was assessed, and the result 
was again negative (Goode et al., 2002). Einarsdottir et al. (2006b) chose six 
SNPs in CHEK2 and investigated the association between breast cancer risk and 
survival with regard to variation in CHEK2. They also found no association 
between CHEK2 variation and breast cancer risk or survival (Einarsdottir et al., 






CHEK2 is associated with an adverse prognosis in glioblastoma multiforme 
(Simon et al., 2006)  
2.5.4.5 Contribution of CHEK2 mutations to various cancer types 
The contribution of CHEK2 mutations have been examined in cancers of several 
organs. Since the main focus of this study was in breast and colorectal cancers, 
they are discussed in more detail under specific headings. The contribution of 
1100delC to cancer risk in several cancer types has been researched vigorously 
in recent years.  
 
When CHEK2 1100delC was first found to be associated with hereditary breast 
cancer, the association was evaluated also in families with ovarian cancer cases. 
No increased risk for ovarian cancer was associated with CHEK2 1100delC when 
comparing breast cancer only with breast-ovarian cancer families (Meijers-
Heijboer et al., 2002; Vahteristo et al., 2002) or with ovarian cancer cases (Baysal 
et al., 2004; Cybulski et al., 2004a). CHEK2 1100delC was identified with a high 
frequency in families with both breast and colorectal cancers, which has even led 
to the suggestion of a new hereditary cancer phenotype called hereditary breast 
and colorectal cancer (HBCC) (Meijers-Heijboer et al., 2003). Several studies 
have since challenged this proposal by investigating the association between 
colorectal cancer and 1100delC (III; de Jong et al., 2005; Brinkman et al., 2006; 
Naseem et al., 2006). Studies in prostate cancer have shown less straightforward 
results; 1100delC was associated with hereditary prostate cancer in Finland 
(Seppälä et al., 2003), but other reports failed to prove a statistically significant 
association with CHEK2 1100delC (Dong et al., 2003; Cybulski et al., 2004b; 
Wagenius et al., 2006). Results are consistent, although frequencies vary 
between populations. In Poland, the truncating mutations (1100delC and 
IVS2+1G>A) together are associated with an increased risk for both familial and 
unselected prostate cancers (Cybulski et al., 2004b). CHEK2 variants have been 
infrequent or the contribution to cancer susceptibility has been nonexistent in 






(Koppert et al., 2004), bladder cancer, laryngeal cancer, lung cancer, pancreatic 
cancer, and stomach cancer (Cybulski et al., 2004a). Variants in CHEK2 in non-
Hodgkin’s lymphoma have been observed (Hangaishi et al., 2002; Tort et al., 
2002), and CHEK2 I157T has also been shown to be associated with an 
increased risk (p=0.05, OR=2.0, 95% CI=1.1-3.8) (Cybulski et al., 2004a). CHEK2 
1100delC does not seem to be associated with multiple primary cancers (Huang 
et al., 2004), and in general, the cancer susceptibility conferred by 1100delC 
appears to be limited to breast cancer (Thompson et al., 2006), although a very 
recent report with large study material suggest that 1100delC may also increase 
risk of other cancers (Weischer et al., 2007). 
2.5.5 CHEK2 mutations in tumors 
Somatic mutations in CHEK2 are relatively rare (Ingvarsson et al., 2002; Bartek 
and Lukas, 2003; Williams et al., 2006). While no regularly occurring mutations 
exist, reports have been madeof single or a few cases in different cancer types. 
Somatic mutations in CHEK2 have been observed in breast cancer (Sullivan et 
al., 2002), osteosarcomas, lung cancer, and ovarian cancer (Miller et al., 2002). 
Haruki et al. (2000) reported somatic CHEK2 D311V in lung cancer, and this 
D311V was shown to exhibit impaired kinase activity and reduced expression 
(Matsuoka et al., 2001). Somatic mutations in CHEK2 have also been identified in 
prostate cancer (R117G and E321K) (Wu et al., 2006) and in a case of 
myelodysplastic syndrome (A507G) (Hofmann et al., 2001). In addition, malignant 
gliomas have been studied, but no mutations have been identified (Ino et al., 
2000). Also in glioblastomas the only variations observed in CHEK2 were 
1100delC and I157T, which were probably germline mutations, and they were 







2.5.6 Loss of heterozygosity at CHEK2 
Observed loss of heterozygosity (LOH) at a certain chromosomal location is 
considered an indication of a tumor suppressor gene location. This, however, is 
not always true the other way round; as discussed earlier, tumor suppressor 
mutations can affect function in various ways (Santarosa and Ashworth, 2004). 
  
Several studies have searched for LOH at CHEK2 location 22q in tumors. 
Although comparing LOH studies is challenging because of different markers 
used, studies have generally come to the conclusion that tumorigenesis 
associated with CHEK2 mutations may not involve LOH, or at least it may not be 
the only mechanism inactivating the wt allele (Oldenburg et al., 2003; Sodha et 
al., 2002a; Sodha et al., 2006). A functional study on cell lines carrying CHEK2 
1100delC supports this view since the number of functional CHEK2 in these cells 
is half thst of wt cells, suggesting that 1100delC contributes to carcinogenesis by 







3 Aims of the study 
When this thesis work started, CHEK2 1100delC was just about to be established 
as the first low-penetrance susceptibility allele in breast cancer, and the missense 
variant CHEK2 I157T had been recently identified in breast cancer cases. 
 
The aims of this study were to evaluate: 
 
1. the role of the CHEK2 gene for breast cancer predisposition in Finnish breast 
cancer families and for breast cancer risk at the population level  
 
2. the clinical and biological characteristics of the breast tumors associated with 
the CHEK2 germline mutations or aberrant CHEK2 protein expression 
 
3. the role of CHEK2 mutations, namely 1100delC and I157T, in colorectal cancer 







4 Material and methods 
4.1 Samples 
4.1.1 Breast cancer patient samples 
The series of 1035 unselected breast cancer cases has originally been described 
in Syrjäkoski et al. (2000), and it includes consecutive newly diagnosed breast 
cancer patients recruited between 1997 and 1998 at the Helsinki University 
Central Hospital, Department of Oncology (n=627), and between 1997 and 1999 
at the Tampere University Hospital (n=408). It covers 82% (87% in Helsinki and 
75% in Tampere) of all breast cancer patients treated at the respective hospitals 
during the study period. This series has been used in Studies I and II. 
 
Another series of unselected breast cancer cases was used and also described 
for the first time in Study II. This series includes 262 consecutive newly diagnosed 
breast cancer patients recruited between January and June in 2000 at the 
Helsinki University Central Hospital, Department of Oncology. This series covers 
65% of all breast cancer cases treated during the study period. 
 
Familial breast cancer case series (n=507) used in Study I includes 216 index 
cases with a stronger family history of breast and/or ovarian cancer (three or more 
breast/ovarian cancer cases in first-, or second-degree relatives including the 
proband) and separately 291 index cases with only one affected first-degree 
relative. This series has been previously described in Vahteristo et al. (2001b). 
The screening for BRCA1 and BRCA2 mutations in this series has been 
described in Vahteristo et al. (2001a) and Vehmanen et al. (1997). Data 
concerning the characteristics of tumors and the clinical data were collected from 
patient files. All cancer diagnoses were confirmed through the Finnish Cancer 







4.1.2 Breast tumor arrays for CHEK2 immunohistochemistry 
The construction of tumor arrays and the immunohistochemistry protocol for 
estrogen receptor (ER), progesterone receptor (PR), and p53 have been 
previously described in detail (Kononen et al., 1998; Torhorst et al., 2001). A 
breast cancer array of 124 tumors from 75 Finnish BRCA1/2-negative breast 
cancer families was used in Study I. In Study II, a breast tumor array of 611 
unselected breast tumors was used. These samples were collected in 1985-1994 
at the University Hospital in Basel (Basel, Switzerland), Women’s Hospital 
Rheinfelden (Rheinfelden, Germany), and the Kreiskrankenhaus Lörrach 
(Lörrach, Germany). Formalin-fixed, paraffin-embedded tumor material was 
available from the Institute of Pathology, University of Basel. Information on 
pathologic stage, tumor diameter, and nodal status was collected from the 
pathology reports. All slides from all tumors were reviewed by one pathologist to 
define the histological grade and the histologic tumor type. Detailed information on 
samples is given in Poremba et al. (2002). 
4.1.3 Colorectal cancer patient samples 
A Finnish population-based series of 1042 colorectal cancer cases was collected 
at nine central hospitals in southeastern Finland between 1994 and 1998. This 
material was used in Studies III (partly) and IV. The patient series has been 
described in detail in Aaltonen et al. (1998) and Salovaara et al. (2000). Clinical 
data (used in Study IV) for the patients include age at diagnosis, family history of 
cancer, information from pathology reports, and tumor grade.In addition, other 
unselected CRC cases from Helsinki University Central Hospital and Central 
Finland Central Hospital (Jyväskylä) were used in Study III (n=44). 
 
Familial colorectal cancer case was defined in these studies as a colorectal 








4.1.4 Population samples 
The series of 1885 healthy control individual peripheral blood samples was 
collected at the Finnish Red Cross Blood Transfusion Service’s eight regional 
centers (Jyväskylä, Kuopio, Lappeenranta, Oulu, Pori, Tampere, Turku, and 
Vaasa), representing different geographical regions in Finland.  
 
4.1.5 Criteria for Hereditary Breast and Colorectal Cancer Phenotype 
(HBCC) 
The HBCC phenotype has been described by Meijers-Heijboer et al. (2003) and 
the criteria are as follows. A HBCC family includes at least two first- or second-
degree relatives affected with breast cancer, at least one of whom had been 
diagnosed before 60 years of age and either 1) at least one breast cancer case 
with CRC, or 2) a first/second-degree relative of a breast cancer case diagnosed 
with CRC before 50 years of age, or 3) two or more CRC cases, at least of whomt 
one was a first/second-degree relative of a breast cancer case.  
4.2 Methods 
4.2.1 DNA extraction 
Genomic DNA from breast cancer patients and controls was extracted from 
peripheral blood leukocytes by using a standard phenol-chloroform method. 
Colorectal cancer patient DNA was extracted from either colon mucosa or blood 
leukocytes by a standard nonenzymatic method (Lahiri and Nurnberger, 1991). 
The method was also applied for DNA extraction from colorectal cancer samples 
that had been evaluated by a pathologist prior to extraction to display more than 







Minisequencing (also known as primer extension) is a method developed by 
Syvänen et al. (1993) that utilizes the specificity of DNA polymerase to 
incorporate a single nucleotide at the 3’-end of a sequence specific primer. Solid-
phase minisequencing is typically used for detecting (known) point 
mutations/SNPs in PCR-amplified products. One of the primers used in the PCR 
reaction is biotinylated, which enables the attachment of DNA to the streptavidin-
coated solid phase. The optimal size for the PCR product is 100-250 nt. DNA is 
denaturated by NaOH. A mixture of DNA polymerase, mutation/SNP-specific 
primer, and 3H-labeled nucleoside is applied. The same sample is pipetted into 
two wells of a plate with two different nucleosides in the mixture (one NTP for the 
wt and one for the mutant allele). Radiation is quantified by a scintillation counter, 
and the results of the two wells are compared. 
4.2.3 Conformation-sensitive gel electrophoresis 
Conformation-sensitive gel electrophoresis (CSGE), introduced by Ganguly et al. 
(1993), was used in Studies I, II, III, and IV. The CSGE method is based on 
heteroduplex formation between two PCR-amplified DNA strands harboring 
mismatched nucleotides, which results in a mobility shift in the gel compared with 
a homoduplex. PCR products were denatured for 10 min at 95°C, and 
heteroduplexes were formed when reactions were allowed to cool down to room 
temperature in 45 min. Reactions were run in a mildly denaturing CSGE gel (10% 
acrylamide, 15% formamide, and 10% ethylene glycol) at 3 W overnight and 
visualized by silver-nitrate (AgNO3) staining or by labeling one primer with 33P and 
exposing the dried gel on a BioMax film (Kodak, Rochester, NY, USA). 
4.2.4 Restriction fragment length polymorphism analysis 
RFLP analysis was utilized in Study II for screening CHEK2 I157T variant in 
colorectal cancer patients and controls. CHEK2 exons 2-3 were amplified from 






(5’-CATATTCTGTAAGGACAGGAC), and the PCR product was digested with 
restriction endonuclease BtsI (New England Biolabs, Beverly, MA, USA). The 
resulting fragments were separated using 2% agarose gel electrophoresis. The 
BtsI enzyme digests a PCR product with the wt allele once and a PCR product 
with the T470C (I157T) allele twice. 
 
The unpublished screening of CHEK2 IVS2+1G>A was carried out using the 
aforementioned PCR primers for CHEK2 exons 2-3. The PCR product was 
digested by restriction endonuclease HPY188III (New England Biolabs, Beverly, 
MA, USA), and the resulting fragments were separated in 2% agarose gel 
electrophoresis. 
4.2.5 Direct DNA sequencing 
DNA sequencing has been used in all studies for confirming detected variants by 
other methods, for identifying the mobility shiftcausing sequence variant in DNA, 
and in Study III also to detect LOH at CHEK2 exon 10. Briefly, the genomic DNA 
region of interest was first amplified by PCR and purified using either a QIAquick 
PCR Purification Kit (Qiagen, Valencia, CA, USA) or ExoSAP-IT (USB, Cleveland, 
OH, USA) according to the manufacturer’s instructions. Sequencing reactions 
were carried out using a BigDye Terminator kit v 3.0 / 3.1 (Applied Biosystems, 
Foster City, CA, USA), and reactions were purified by acetate-ethanol 
precipitation. Reactions were run and analyzed in an ABI310 Automated 
Sequencer (Applied Biosystems, Foster City, CA, USA). 
4.2.6 Immunohistochemistry 
Immunohistochemical staining of breast tumor microarray with CHEK2 
monoclonal antibody was used in Studies I and II. The staining method for the 
monoclonal antibody (DCS-270 against the aminoterminal SQ/TQ-rich domain of 
human CHEK2) has been described in Bartkova et al. (2001) and Lukas et 






4.2.7 Functional studies on CHEK2 
The methodology for CHEK2 I157T functional investigations (transient 
transfections, cycloheximide treatments, and irradiation of cells) in Study I has 
been described in detail elsewhere (Bartkova et al., 2001; Falck et al., 2001a; 
Falck et al., 2001b).  
4.2.8 Statistics 
Statistical package SPSS for Windows (SPSS Inc., Chicago, IL, USA) or SISA 
(http://home.clara.net/sisa/) was used for all analyses. Statistical significance of 
associations was evaluated using chi-squared test or Fisher’s exact test in all 
studies. Survival analyses were performed calculating Kaplan-Meier curves and 
comparing the subsets of cases using a log rank test. Two-sided p-values ≤0.05 
were considered significant. 
4.3 Ethical issues 
All studies were carried out with the informed consent of patients and approval 
from the ethics committees of the respective hospitals as well as from the Ministry 







5.1 Association of CHEK2 I157T with breast cancer (I) 
Subsequently to establishment of CHEK2 1100delC as a low-penetrance breast 
cancer susceptibility allele (Meijers-Heijboer et al., 2002; Vahteristo et al., 2002), 
the I157T missense variant in CHEK2 was studied for breast cancer 
predisposition. 
 
A total of 1383 breast cancer cases and 1885 population controls were screened 
for CHEK2 I157T, identifying 99 carriers among cases and 100 among controls 
(see Table 3). The population frequency of CHEK2 I157T in Finland was thus 
defined as 5.3%, with little to no geographical variation. In the population-based 
series, the frequency of CHEK2 I157T was 7.4% (77/1035), which is significantly 
higher than the frequency in controls (p=0.02, OR=1.43, 95% CI=1.06-1.95). The 
carrier frequency among familial breast cancer cases (5.5%, 28/507) was similar 
to population controls (p=0.85, OR=1.04, 95% CI=0.68-1.61). CHEK2 I157T 
confers a 1.4-fold risk of breast cancer for carriers.  
Table 3. Frequency of CHEK2 I157T in breast cancer cases and controls. 
+ve/Total % p 1 OR1 95% CI
Controls 100/1885 5.3
All breast cancer cases 99/1383 7.2 0.029 1.38 1.03-1.83
Unselected breast cancer cases 77/1035 7.4 0.021 1.43 1.06-1.95
Familial breast cancer cases 28/507 5.5 0.847 1.04 0.68-1.61
   Breast cancer only 24/448 5.4 0.965 1.01 0.64-1.60
   Breast and ovarian cancer families 4/59 6.8 0.554 1.30 0.46-3.65
   Index with only one affected 1st-degree relative 142/291 4.8 0.725 0.90 0.51-1.60
   Three or more affected in the family (in 1st- or 2nd-degree relatives) 14/216 6.5 0.470 1.23 0.69-2.20
1compared with controls
2includes two homozygotes  
5.2 Genetic variants in CHEK2 (I) 
Screening of 14 CHEK2 coding exons and exon-intron boundaries in 75 breast 
cancer families resulted in identification of nine different sequence variants. 






addition to these recognized CHEK2 variants, a silent mutation 252A>G (E84E) 
and six intronic changes were observed. All intronic variants reside quite far from 
the exon-intron junctions. Variants and their frequencies are presented in Table 4. 










1462-25A>G 3  
5.3 Functional studies on CHEK2 I157T and CHEK2 protein 
expression in breast cancer (I) 
The CHEK2 I157T protein was compared with the wt CHEK2 protein as well as 
with another FHA domain variant CHEK2 R145W, which is known to be unstable 
(Bartkova et al., 2001; Lee et al., 2001). CHEK2 I157T behaves like wt CHEK2 
with respect to stability (protein level) and ionizing radiation (IR) -induced 
modification in vivo (phosphorylation). Dimerization of CHEK2 is an important step 
in CHEK2 activation after IR (Ahn et al., 2002; Xu et al., 2002). Differentially 
tagged inactive CHEK2 wt and CHEK2 I157T were coexpressed in cell lines, and 
formation of both homodimers (wt-wt and I157T-I157T) as well as heterodimers 
(wt-I157T) was observed. Given the inability of CHEK2 I157T to efficiently bind 
and phosphorylate its substrates, it may interfere with functional CHEK2 proteins, 
diminishing the functional CHEK2 pool in a cell. 
 
Immunohistochemical staining of CHEK2 in a breast cancer array of 124 tumors 
confirms the results of functional studies on CHEK2-I157T stability. This tumor 
array included five tumors from CHEK2 I157T carriers. In four of five cases, 
tumors showed normal CHEK2 protein expression, and in one case the 






5.4 Characteristics of tumors with aberrant CHEK2 expression (II) 
Immunohistochemical staining of CHEK2 in tumor array of 611 unselected breast 
tumors was successful for 440 tumors. The results were categorized into four 
groups: reduced intensity of staining in the carcinoma cells (5/440, 1.1%), reduced 
number of positive carcinoma cells (67/440, 15.2%), reduced intensity and 
number of positive carcinoma cells (21/440, 4.8%), and normal staining pattern 
(347/440, 78.9%) compared with staining of normal breast tissue. CHEK2 protein 
expression was reduced in 21.1% of breast tumors analyzed (93/440). 
Characteristics of tumors, grouped according to CHEK2 expression, are 
presented in Table 5. Generally, tumors with reduced CHEK2 expression do not 
differ from tumors where CHEK2 expression is intact. The mean age of diagnosis 
for both groups was 61 years, and no difference in overall survival of patients was 
observed. Tumors with aberrant CHEK2 expression, however, seem to be larger 
than other tumors (pT1-2 vs. pT3-4, p=0.002). 35.2% of pT3-4 tumors were 
CHEK2 aberrant compared with 18.6% of pT1-2 tumors. Especially, pT4 tumors 
are more common among those with aberrant CHEK2 expression than among 
those with normal expression (21/93, 22.6% and 31/344, 9.0%; respectively; 
p=0.0003, OR=2.9, 95% CI=1.6-5.4). Twenty-one of the 440 tumors showed 
aberrant staining with regard to both staining intensity and number of stained 
carcinoma cells. Since CHEK2 expression is the most aberrant in these tumors, 
this group was carefully studied for associations with any tumor characteristics; 
however, the small number of tumors limits statistically significant observations. 
The most interesting finding was that 94% (16/17) of the most aberrantly stained 














Table 5. Tumor characteristics of 611 unselected breast tumors grouped according 
to CHEK2 expression status. (Adapted from Kilpivaara O. et al.: 
Correlation of CHEK2 protein expression and c.1100delC mutation status 
with tumor characteristics among unselected breast cancer patients. 





ductal 450 (73.6) 262 (75.5%) 77 (82.8%)
lobular 81 (13.3) 41 (11.8%) 5 (5.4%)
medullary 19 (3.1) 14 (4.0%) 2 (2.2%)
other 61 (10.0) 30 (8.6%) 9 (9.7%)
Tumor grade (n=611) 0.346
1 169 (27.7) 85 (24.5%) 26 (28.0%)
2 260 (42.6) 141 (40.6%) 42 (45.2%)
3 182 (29.8) 121 (34.9%) 25 (26.9%)
Estrogen receptor status (n=483) 0.124
positive 360 (79.5) 209 (76.3%) 61 (84.7%)
negative 93 (20.5) 65 (23.7%) 11 (15.3%)
Progesterone receptor status (n=437) 0.352
positive 216 (49.4) 140 (40.3%) 31 (46.3%)
negative 221 (50.6) 126 (36.3%) 36 (53.7%)
Tumor size (pT) (n=605) 0.002
1-2 515 (84.3) 298 (86.6%) 68 (73.1%)
3-4 90 (14.7) 46 (13.4%) 25 (26.9%)
Lymph node status (pN) (n=573) 0.116
positive (1-2) 279 (48.7) 157 (48.6%) 50 (58.1%)
negative 294 (51.3) 166 (51.4%) 36 (41.9%)
p53 immunohistochemistry (n=434) 0.220
normal (negative) 348 (80.2) 204 (77.9%) 60 (84.5%)








5.5 Characteristics of CHEK2 1100delC carrier tumors (II, 
Kilpivaara et al., unpublished) 
The set of 1297 unselected breast cancer cases had altogether 1365 primary 
breast tumors, and clinical and histopathologic information was available for 1338 
tumors. An association was observed between CHEK2 1100delC carriers and 
higher tumor grade (p=0.021). Specifically, there were less grade one tumors 
among CHEK2 1100delC carriers than among noncarriers (p=0.008). A higher 
frequency of ER-positive tumors was noted among CHEK2 1100delC carriers 
(91.2% vs. 78.3%, p=0.071), and although not statistically significant, this finding 
is in line with the observation of high frequency of ER-positive tumors among 
crossly reduced CHEK2 immunohistochemical staining. Generally, the tumors 
from CHEK2 1100delC carriers and noncarriers were similar. The mean age at 
diagnosis was 57 years. The strongest association of CHEK2 1100delC was 
observed with bilaterality, as also reported previously (Vahteristo et al., 2002). 
The proportion of bilateral tumors among CHEK2 1100delC tumors was 
significantly higher than the proportion of bilateral tumors among noncarriers 
(18.8% vs. 4.9%, p=0.005). Detailed information of tumor characteristics and the 
association with CHEK2 1100delC is presented in Table 6. 
 
We also analyzed survival among all our breast cancer cases who were evaluated 
for CHEK2 1100delC and were eligible for survival analysis (n=743), mean follow-
up 1385 days, 95% CI=1345-1426, limited to 5 years (1826 days)) (Kilpivaara et 
al., unpublished). CHEK2 1100delC was not associated with overall (or breast 
cancer-specific) survival of patients in our material. The disease-free survival was 
poorer in 1100delC carriers (p=0.03) and was likely due to poorer survival with 
regard to diagnosis of contralateral breast cancer (p=0.001) (see Figure 3). The 
disease-free survival with regard to a recidive tumor, distant metastasis, or 










Table 6. Characteristics of 1338 tumors from 1297 unselected breast cancer 
patients analyzed for CHEK2 1100delC. (Adapted from Kilpivaara O. et al., 
International Journal of Cancer, 113(4): 575-580, 2005.) 
p
Total (%) wt 1100delC
1338 1301 (97.2) 37 (2.8)
Histology (n=1328)
ductal 966(72.2) 935 (71.9) 31 (83.8)
lobular 190 (14.2) 188 (14.5) 2 (5.4)
medullary 16 (1.2) 15 (1.2) 1 (2.7)
other 156 (11.7) 154 (11.9) 2 (0.6)
Tumor grade (n=1119) 0.021
1 300 (26.8) 298 (27.4) 2 (6.3)
2 496 (44.3) 476 (43.8) 20 (62.5)
3 323 (28.9) 313 (28.8) 10 (31.3)
Estrogen receptor status (n=1242) 0.071
positive 977 (78.8) 946 (78.3) 31 (91.2)
negative 265 (21.3) 262 (21.7) 3 (8.8)
Progesterone receptor status (n=1243) 0.963
positive 809 (65.1) 787 (65.1) 22 (64.7)
negative 434 (34.9) 422 (34.9) 12 (35.3)
Tumor size (pT) (n=1278) 0.145*
1-2 1207 (94.4) 1174 (94.6) 33 (89.2)
3-4 71 (5.6) 67 (5.4) 4 (10.8)
Lymph node status (pN) (n=1224) 0.412
negative 712 (58.2) 694 (58.4) 18 (51.4)
positive (1-2) 512 (41.8) 495 (41.6) 17 (48.6)
Distant metastasis (n=1235) 0.813
negative 1188 (96.2) 1156 (96.2) 32 (97.0)
positive 47 (3.8) 46 (3.8) 1 (3.0)
Laterality (n=1297)
bilateral breast carcinoma 68 (5.2) 62 (4.9) 6 (18.8) 0.005*
unilateral breast carcinoma 1229 (94.8) 1203 (95.1) 26 (81.3)
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Figure 3 Kaplan-Meier survival curves for disease-free and contralateral breast cancer-
free survival with regard to CHEK2 1100delC carriership.  
5.6 Characteristics of CHEK2 I157T – positive tumors (Kilpivaara 
et al., unpublished) 
We analyzed the characteristics of 745 breast tumors from 697 unselected breast 
cancer cases, including 53 cases with bilateral disease (101 tumors) (Syrjäkoski 
et al., 2000; II). Tumors from CHEK2 I157T carriers are of lower grade than those 
from noncarriers (p=0.01). (The proportions of CHEK2 I157T carriers among 
grade 1, 2, and 3 tumors are 11.0%, 5.4%, and 3.7%, respectively.), Otherwise 
the tumors are very similar. Furthermore, there is no difference in either overall or 
disease-free survival (metastasis-free, cancer-free, contralateral breast cancer-
free, recidive-free, and all combined) between CHEK2 I157T carriers and 
noncarriers (data not shown). The details of tumors characteristics are presented 












Table 7. Characteristics of 745 breast tumors from 697 unselected breast cancer 
patients analyzed for CHEK2 I157T. 
p
Total (%) wt I157T
745(100.0) 699(93.8) 46(6.2)
Histology (n=705)
ductal 519(69.8) 487(65.5) 32(69.6)
lobular 118(15.9) 110(15.8) 8(17.4)
medullary 8(1.1) 8(1.1) 0(0.0)
other 60(8.5) 56(8.5) 4(9.1)
Tumor grade (n=675) 0.01
1 163(24.1) 145(22.9) 18(42.9)
2 298(44.1) 282(44.5) 16(38.1)
3 214(31.7) 206(32.5) 8(19.0)
Estrogen receptor status (n=704) 0.93
positive 553(78.6) 519(78.5) 34(79.1)
negative 151(21.4) 142(21.5) 9(20.9)
Progesterone receptor status (n=704) 0.29
positive 489(69.5) 456(69.0) 33(76.7)
negative 215(30.5) 205(31.0) 10(23.3)
Tumor size (pT) (n=725) 1.00*
1-2 671(92.6) 629(92.5) 42(93.3)
3-4 54(7.4) 51(7.5) 3(6.7)
Lymph node status (pN) (n=721) 0.55
negative 387(53.7) 362(53.4) 25(58.1)
positive (1-2) 334(46.3) 316(46.6) 18(41.9)
Distant metastasis (n=709) 0.46*
negative 672(94.8) 635(94.9) 37(92.5)









5.7 CHEK2 1100delC in colorectal cancer susceptibility and 
HBCC (III) 
Screening colorectal cancer cases for CHEK2 1100delC resulted in identification 
of 17 carriers among 662 cases (2.6%). The frequency was 1.3% (2/149) among 
cases with a family history of colorectal cancer, and nominally higher in cases 
without a family history of colorectal cancer (15/513, 2.9%). The frequency of 
CHEK2 1100delC is higher in Eastern Finland than in other parts of Finland. Since 
the majority of CRC cases originated from Eastern-Central Finland, we adjusted 
the population control frequency to match the geographical distribution of patients 
(matched frequency 1.9%). No significant difference was observed in frequencies 
between CRC cases and population controls, p-values and odds ratios with 95% 
confidence intervals for all cases, familial cases, and nonfamilial cases are 
p=0.266, OR=1.393, 95% CI=0.775-2.504; p=1.000 OR=0.720, 95% CI=0.172-
3.020; and p=0.134 OR=1.592, 95% CI=0.863-2.939, respectively. 
 
Eighty families (15.8%) of our set of 507 familial breast cancer cases previously 
analyzed for CHEK2 1100delC (Vahteristo et al., 2002) also contain CRC cases, 
and 19 of these (3.7% of all) fulfill the definition of HBCC. The frequency of 
CHEK2 1100delC was very similar in breast cancer families with or without CRC 
cases (4/80, 5.0% among breast and CRC families; 1/19, 5.3% among HBCC 
families; and 24/427, 5.6% among breast cancer families). 
 
All 17 CRC cases (2 familial cases and 15 nonfamilial cases) who carried the 
CHEK2 1100delC mutation were analyzed for loss of heterozygosity (LOH) at 
CHEK2 exon 10 in their colorectal tumors. LOH was observed in three cases (one 
familial, two nonfamilial). In two cases, the wt allele was lost, and in one 






5.8 CHEK2 I157T is associated with familial and sporadic 
colorectal cancer (IV) 
A total of 972 colorectal cancer patient (noncancerous tissue) samples were 
successfully analyzed for CHEK2 I157T. Seventy-six carriers (7.8%) of this variant 
were identified. This frequency is significantly higher than in the normal Finnish 
population (5.3%, OR=1.5, 95% CI=1.1-2.1, p=0.008). The frequency of CHEK2 
I157T was even higher among CRC patients with a family history of colorectal 
cancer (10.4%). The details of frequencies in different groups are presented in 
Table 8. Furthermore, the relationships between characteristics of colorectal 
tumors and CHEK2 I157T status were examined. None of the characteristics 
(tumor location, tumor grade, tumor stage (Dukes), RER status) was associated 
with CHEK2 I157T. Age at diagnosis was also similar in variant carriers and non-
carriers (67 years). CHEK2 I157T was more frequent in cases with a family history 
of any type of cancer (three or more cancer cases in first-degree family members, 
including the index case); 29/290, 10.0% vs. 47/679, 6.9% (p=0.10). In addition, 
patients with multiple primary tumors were more likely to be carriers of CHEK2 
I157T (16/140, 11.4% vs. 60/832, 7.2%; p=0.09). 
Table 8. Frequency of CHEK2 I157T in colorectal cancer cases and controls. 
+ve/Total % p * OR* 95% CI
Controls 100/1885 5.3 1.0
All CRC Cases 76/972 7.8 0.008 1.5 1.1-2.1
   Familial CRC Cases 14/135 10.4 0.01 2.1 1.1-3.7
   Non-familial CRC Cases 62/837 7.4 0.03 1.4 1.0-2.0
*vs. population controls
Family history of cancer is defined as three or more cancer cases in first-degree family members, including the index case.














6.1 CHEK2 I157T in breast cancer predisposition (I) 
CHEK2 germline variant I157T is associated with breast cancer risk. The 
associated risk is, however, smaller than the twofold risk conferred by CHEK2 
1100delC (Vahteristo et al., 2002). Unlike 1100delC, this variant is not associated 
with a family history of breast cancer, although both identified homozygous 
carriers of I157T had a first-degree relative with breast cancer. The population 
frequency of I157T is relatively high in Finland. In addition to our observation 
(5.3%), another study reported a frequency of 6.5% (13/200) in Northern Finland 
(Allinen et al., 2001). A similar figure was reported from Poland, where the 
frequency of CHEK2 I157T is 4.8% (193/4000) (Cybulski et al., 2004a). An even 
stronger association was observed in a study with combined Byelorussian and 
German breast cancer cases (OR=4.1, 95% CI= 1.8-9.2, p<0.001) (Bogdanova et 
al., 2005). CHEK2 I157T seems to be a genetic variant specific to 
Northern/Eastern European populations. In other studied populations, the variant 
is apparently very rare or absent (Table 9) (Friedrichsen et al., 2004; Schutte et 
al., 2003). Based on breast cancer incidence in Finland (IARC, 1997), this variant 
would confer an estimated absolute risk of 8.1% by age 70, compared with 5.5% 
absolute risk in noncarriers, and 2.2% of all breast cancer cases in Finland would 
be attributable to CHEK2 I157T. Studies on CHEK2 in Finland and Poland have 
shown similar results on variant I157T frequencies in breast, colorectal, and 
prostate cancer (Table 9). The frequencies of other CHEK2 variants vary between 
Finland and Poland; the frequency of 1100delC is higher in Finland, whereas the 
frequency of IVS2+1G>A is higher in Poland (Cybulski et al., 2004a; Vahteristo et 
al., 2002; Kilpivaara et al., unpublished). The large deletions in CHEK2 observed 
in Poland are currently under investigation in Finland (unpublished data).  
 
In screening of the CHEK2 coding region for germline variants in breast cancer 






four cases of both 1100delC and I157T, which were the only alterations that would 
likely lead to a change in the CHEK2 protein.  
 
The CHEK2 I157T protein seems to be stable compared with CHEK2 1100delC 
and R145W (Bartkova et al., 2001; Lee et al., 2001). Similar observations were 
also made when CHEK2 I157T was studied in functional assays; CHEK2 I157T 
behaves like wt CHEK2 when it comes to stability and modification after IR 
exposure.  Previous studies have, however, proven that CHEK2 I157T is defective 
in phosphorylating and binding its substrates, including p53, Cdc25A, and BRCA1 
(Falck et al., 2001a; Falck et al., 2001b; Li et al., 2002). Furthermore, CHEK2 
I157T has been reported to undermine the normal functions of CHEK2 when 
coexpressed in human cell culture (Falck et al., 2001b). Since dimerization is an 
important step in DNA damage-induced CHEK2 activation, the observation that 
CHEK2 I157T can form a dimer with wt CHEK2 is of great importance. The 
defective characteristics of CHEK2 I157T may thus have an effect on the 
functional CHEK2 pool in a cell.  
 
Immunohistochemical studies on breast tumors from CHEK2 I157T carriers 
showed no marked difference in CHEK2 expression patterns or expression levels 
compared to tumors of wt CHEK2 carriers. 
6.1.1 Characteristics of CHEK2 I157T – positive tumors (Kilpivaara et al., 
unpublished) 
CHEK2 I157T has been suggested to be strongly associated with breast cancer of 
lobular histology (Huzarski et al., 2005). We studied the characteristics of breast 
tumors in our material, but we found no association with lobular histology. The 
frequency of I157T among lobular cancers was 6.8%, which is slightly higher than 
the 6.2% observed among all tumor histologies, but this is not a significant 
difference. The only significant finding was an association of CHEK2 I157T with 
lower grade (grade 1) tumors. However, the number of tumors in the CHEK2 
I157T group was quite small (n=46), and thus one needs to be careful when 






CHEK2 mutation-positive breast tumors among younger women (age at diagnosis 
< 51 years). Interestingly, they combined all CHEK2 mutation carriers into one 
group and compared them with noncarriers. The majority of CHEK2 mutation 
carriers are, however, carriers of I157T (207/252), and thus, the characteristics of 
mutation carriers largely reflect the characteristics of I157T carriers. Cybulski et al. 
(2006) report an association with lobular histology and also characterize the 
CHEK2 mutation carrier tumors as being larger and the mutation carriers as more 
often having a family history of breast cancer. Their conclusion is supported by 
our observation that tumors from CHEK2 mutation-positive cases are similar to 
breast cancers in the population at large. We saw no difference in either disease-
free survival or overall survival between CHEK2 I157T carriers and noncarriers. In 
another study, however, metastasis-free survival of CHEK2 I157T carriers was 
reported to be worse than that of noncarriers based on a very small number of 
cases (n=13) (Meyer et al., 2007). 
6.2 Characteristics of breast tumors from CHEK2 1100delC 
carriers (II; Kilpivaara et al., unpublished) 
Characteristics of breast tumors may give cues to predict prognosis and may help 
in determining the optimal treatment for a cancer type. CHEK2 protein expression 
has been found to be absent or grossly reduced in tumors from CHEK2 1100delC 
carriers, which is in accordance with the truncating nature of the mutation 
(Vahteristo et al., 2002; Oldenburg et al., 2003).  CHEK2 1100delC has previously 
been shown to be strongly associated with family history of breast cancer 
(Meijers-Heijboer et al., 2002; Vahteristo et al., 2002) and with bilateral disease 
(Vahteristo et al., 2002; de Bock et al., 2004). In our analysis of 1297 unselected 
breast cancer cases exploring relationships of tumor characteristics or 
clinicopathologic features with CHEK2 1100delC, we observed CHEK2 1100delC 
to be associated with higher tumor grade (p=0.02). Nearly 94% of tumors from 
CHEK2 1100delC carriers were grade 2-3, when the corresponding number for 
tumors from wt CHEK2 patients was 73%. Schmidt et al. (2007) studied younger 






grades. CHEK2 1100delC tumors seem, however, to be estrogen receptor–
positive, although the difference here is not statistically significant. An association 
with positive hormone receptor status was observed for both estrogen and 
progesterone receptors in a Dutch study (de Bock et al., 2004), and the 1100delC 
was shown to be more prevalent among ER-positive tumor carriers (de Bock et 
al., 2006; Schmidt et al., 2007). A report of 13 carrier tumors suggested a 
contradictory view, with CHEK2 1100delC being associated with breast carcinoma 
carrying characteristics of the basal phenotype (Dede et al., 2006) such as high 
histological grade, lack of hormone receptors, and HER-2 expression (Banerjee et 
al., 2006).  
 
In our study, the strongest association of 1100delC was seen with bilaterality of 
the disease, thus strengthening the previous results. This same phenomenon was 
observed in another study series, where it was also suggested that IR treatment 
could be a risk factor for CHEK2 1100delC carriers for development of 
contralateral breast tumor (Broeks et al., 2004). In addition, similar findings were 
recently reported in Russia, where 1100delC was found to be associated with 
bilateral breast cancer, but also with early onset of the disease (Chekmariova et 
al., 2006). De Bock et al. (2004) also reported poorer disease-free survival for 
CHEK2 1100delC carriers with regard to survival without distant metastases and 
survival without contralateral breast cancer, but did not observe an effect on 
patients’ overall survival. Further results for a similarity between CHEK2 1100delC 
carrier and noncarrier tumors were reported by Schmidt et al. (2007), who also 
observed worse recurrence-free survival that could not be explained by increased 
risk for contralateral breast cancer. We found no difference in overall survival with 
regard to CHEK2 1100delC. Disease-free survival, however, is poorer among 
CHEK2 1100delC carriers, largely due to an increased risk for contralateral breast 
cancer. A very recent study combined CHEK2 mutation carriers (1100delC, I157T, 
and IVS2+1G>A) into one group and observed worse metastasis-free survival 
than in noncarriers of CHEK2 mutations (Meyer et al., 2007). Although their 
material was quite small, their finding is interesting since the cases all received 






room to speculate whether functional CHEK2 is especially needed in cells 
exposed to radiation-inducing DSBs. 
6.2.1 CHEK2 protein expression in breast cancer (II) 
We have previously shown that reduced CHEK2 protein expression is strongly 
associated with CHEK2 germline mutation 1100delC and that an overall reduction 
in expression was present in 21/124 breast tumors (16.9%)  (Vahteristo et al., 
2002). We then analyzed the CHEK2 expression in a separate series of 611 
breast tumors unselected for family history. A similar proportion of tumors with 
reduced CHEK2 expression was identified (21.1%). Tumors with reduced CHEK2 
expression were larger than normally expressing tumors, and especially pT=4 
class tumors were prominent among aberrantly staining tumors (p=0.0003). A 
similar trend was observed among CHEK2 1100delC carriers, but the analysis is 
limited by the small number of 1100delC carriers. An interesting detail is that 
among tumors with the most aberrant CHEK2 expression (reduced number of 
stained cells and reduced intensity of staining) a great majority of tumors are ER-
positive (94%), which is in line with enriched ER-positivity observed among 
CHEK2 1100delC carrier tumors, as well as with a recent report where an inverse 
correlation between CHEK2 and ER expressions was observed (Hinnis et al., 
2007). In our material, CHEK2 expression status of a tumor did not have an effect 
on patients’ overall survival. Honrado et al. (2005) investigated the expression of 
DNA repair proteins in breast tumors and noted that BRCA 1/2-positive tumors 
more often show CHEK2 expression than familial nonBRCA1/2 tumors or 
sporadic tumors. Furthermore, they suggested that by combining CHEK2 with the 
Rad51 protein expression profile, BRCA2-positive tumors could be distinguished 
from familial nonBRCA1/2 tumors (Honrado et al., 2005). 
 
Overall, breast tumors with reduced CHEK2 expression and tumors from CHEK2 
1100delC carriers are similar, which is in line with the association between the 
mutation and aberrant protein expression. However, the 1100delC mutation 






inconsistent observations have been made about LOH, and there may be other 
factors that contribute to somatic CHEK2 inactivation, e.g. through epigenetic 
silencing or variation in splicing (Sullivan et al., 2002; Kato et al., 2004; Staalesen 
et al., 2004). 
6.3 CHEK2 mutations in HBCC and colorectal cancer (III and IV) 
Meijers-Heijboer et al. (2003) originally proposed that CHEK2 1100delC is 
associated with the HBCC (hereditary breast and colorectal cancer) phenotype. 
They observed that 1100delC was more common in families with breast and 
colorectal cancer (n=55) than in families with only breast cancer (18.2% vs. 4.0%) 
(Meijers-Heijboer et al., 2003). We studied the 1100delC mutation in Finnish 
colorectal cancer families and families with defined HBCC phenotype and 
observed no significantly higher frequency of CHEK2 1100delC in CRC patients 
or HBCC families (n=19) compared with population controls or breast cancer 
families. All of the identified CRC patient carriers of CHEK2 1100delC (n=17) were 
analyzed for an allelic imbalance at CHEK2 exon 10, where 1100delC resides. 
Only three cases showed loss of the mutated allele and in one case the wt allele 
was lost in tumor tissue, which supports the observation that CHEK2 1100delC 
may not be a susceptibility allele for CRC. CHEK2 expression has been studied at 
the protein level in 564 colorectal cancer cases, where 29 (5%) had lost CHEK2 
expression and only three of those were carriers of 1100delC, suggesting that 
other mechanisms are involved in inactivating CHEK2 expression (van 
Puijenbroek et al., 2005). 
 
A recent study reports only one 1100delC carrier family among 113 tested British 
HBCC families, thus not supporting CHEK2’s role in HBCC (Naseem et al., 2006). 
In another study, British patients with breast and colorectal cancers were 
screened for 1100delC, but no carriers were identified among 97 cases (Brinkman 
et al., 2006). Isinger et al. (2006) investigated CHEK2 1100delC in tumors of 75 
Swedish patients with metachronous cancer of the breast and colorectum, 






in controls, thus not supporting the idea of CHEK2 1100delC being a risk allele for 
combined breast and colorectal cancer. Also in Sweden, CHEK2 1100delC was 
observed at a similar frequency in CRC cases and controls (Djureinovic et al., 
2006). Furthermore, this lack of CHEK2 1100delC has been reported in 34 
Spanish HBCC families; however, this information is of questionable value since 
no 1100delC carriers have been reported in Spain in general (Collado et al., 2004; 
Osorio et al., 2004; Bellosillo et al., 2005; Sanchez de Abajo et al., 2005). Another 
study from the Netherlands showed similar results to our study, as they also 
observed no association between CHEK2 1100delC and CRC, with frequencies of 
10/629 in unselected CRC cases (1.6%) and 1/230 in controls (0.4%) (de Jong et 
al., 2005). Further evidence that CHEK2 1100delC may not be a CRC 
susceptibility allele comes from a study with colorectal adenoma cases in the UK. 
Again, 1100delC was found at a similar frequency as in population controls 
(3/149, 2.0% vs. 18/1620, 1.1%) (Lipton et al., 2003). CHEK2 1100delC in 
colorectal cancer has been investigated in Poland in combination with other 
truncating mutations in CHEK2 (Cybulski et al., 2007). These authors identified 
only 11 carriers of truncating CHEK2 mutation among 1085 unselected CRC 
cases (1.0%), which is a very similar proportion as among controls (58/5496, 
1.1%). Together these studies show that CHEK2 1100delC is likely not a 
predisposing allele for colorectal cancer, and it also seems unlikely that it would 
be behind the familial aggregation of breast and colorectal cancers, observed in 
the HBCC phenotype. There may, however, be population-specific differences 
and other contributing alleles, making the evaluation of the role of 1100delC 
challenging. 
 
In contrast to CHEK2 1100delC, the I157T variant shows a consistent association 
with colorectal cancer. Cybulski et al. (2004a) first suggested that CHEK2 may be 
a multiorgan cancer susceptibility gene and that I157T was associated with 
cancer at several sites including colorectum. Given that results from Finnish and 
Polish studies on breast and prostate cancers and CHEK2 I157T are fairly 
consistent, we studied the frequency of CHEK2 I157T in Finnish colorectal cases 






Furthermore, we assessed the previously unstudied association of CHEK2 I157T 
with familial CRC. Our results indicate that CHEK2 I157T is associated with 
colorectal cancer risk in Finland, conferring a 1.5-fold risk for carriers (95% 
CI=1.1-2.1, p=0.008). These results are very similar to those of the Polish study 
(Cybulski et al., 2004a). The OR for association with familial CRC was 2.1 (95% 
CI=1.1-3.7, p=0.01). 
 
We also observed a trend towards a higher frequency of I157T in CRC patients 
who have a family history of any cancer type or who themselves have multiple 
primary tumors, supporting the proposed multiorgan susceptibility allele function 
for CHEK2 I157T. Similarly, the I157T variant was more common among our 
unselected breast cancer cases with multiple cancers (other than breast cancer) 
than among those with one primary breast cancer (8/68, 11.8% vs. 36/518, 6.5%) 
(IV). 
 
Cybulski et al. (2007) raised the important and obvious question of wheter the 
truncating and missense mutations have different effects on colorectal cancer risk.  
This has been observed in VHL disease patients, whose risk of 
pheochromocytoma is increased when they have missense mutation in the VHL 
gene, whereas patients with truncating mutations do not develop 
pheochromocytoma (Crossey et al., 1994; Chen et al., 1995). 
 
In addition to I157T, a few other missense mutations have been identified in 
colorectal cancer. Two of 119 Icelandic CRC patients were found to carry CHEK2 
T59K, a missense variant of unknown effect on function. This variant was also 
identified in other cancer cases, but not in controls (Ingvarsson et al., 2002). 
Brinkman et al. (2006) failed to find any 1100delC carriers among combined 
breast and CRC cases, but they did observe two novel missense variants in the 
kinase domain: N405K and Y390C. 
 
Studies on CHEK2 I157T have been limited by this variant seemingly only being 






cancer susceptibility in these populations show a consistent association with 
increased risk of breast, colorectal, and prostate cancers. 
Table 9. Frequency of CHEK2 I157T in breast, prostate, and colorectal cancers in 
different populations. 
Study group % +ve/Total % +ve/Total OR* 95% CI p Reference
Breast cancer
Unselected cases
Finnish 7.4 77/1035 5.3 100/1885 1.4 1.1-2.0 0.02 I (Kilpivaara et al., 2004)
Byelorussian 5.6 24/424 1.3 4/307 4.5 1.6-13.2 0.005 Bogdanova et al., 2005
German 2.2 22/996 0.6 3/486 3.6 1.1-12.2 0.044 Bogdanova et al., 2005
Polish 6.7 68/1017 4.8 193/4000 1.4 1.1-1.9 0.02 Cybulski et al., 2004b
US (Washington, dg<45yrs) 0.4 2/506 0.9 4/459 0.5 0.1-2.5 0.35 Friedrichsen et al., 2004
Familial cases (BRCA1/2 neg)
British 0.0 0/193 0.0 0/448 - - - Schutte et al., 2003
Byelorussian 6.3 6/96 1.3 4/307 5.1 1.4-18.3 0.019 Bogdanova et al., 2005
Dutch 0.0 0/225 0.0 0/181 - - - Schutte et al., 2003
Finnish 8.9 7/79 6.5 13/200 1.4 0.5-3.7 0.49 Allinen et al., 2001
Finnish 5.5 28/507 5.3 100/1885 1.0 0.7-1.6 0.85 I (Kilpivaara et al., 2004)
German 1.9 10/516 1.6 8/500 1.2 0.5-3.1 0.68 Dufault et al., 2004
German 0.6 1/156 0.6 3/486 1.0 0.1-10.1 0.581 Bogdanova et al., 2005
US 0.7 2/272 1.1 1/94 - - - Schutte et al., 2003
BRCA1/2  carriers
British 0.0 0/47 0.0 0/448 - - - Schutte et al., 2003
Dutch 0.0 0/141 0.0 0/181 - - - Schutte et al., 2003
US 0.0 0/147 1.1 1/94 - - - Schutte et al., 2003
Prostate cancer
Unselected cases
Finnish 7.8 42/537 5.4 26/480 1.5 0.9-2.5 0.13 Seppälä et al., 2003
Polish 7.8 54/690 4.8 29/600 1.7 1.1-2.7 0.03 Cybulski et al., 2004a
US (Minnesota), sporadic cases 1.5 6/400 1.2 5/423 0.6 0.2-2.7 0.53 Dong et al., 2003
Familial cases
Finnish 10.8 13/120 5.4 26/480 2.1 1.1-4.3 0.04 Seppälä et al., 2003
Polish 16.3 16/98 4.8 29/600 3.8 2.0-7.4 0.00002 Cybulski et al., 2004a
US (Minnesota) 1.8 7/400 1.2 5/423 1.5 0.5-4.7 0.50 Dong et al., 2003
Colorectal cancer
Unselected cases
Polish 9.3 28/300 4.8 193/4000 2.0 1.3-3.1 0.001* Cybulski et al., 2004b
Finnish 7.8 76/896 5.3 100/1885 1.5 1.1-2.1 0.008 IV (Kilpivaara et al., 2006)
Familial cases









7 Concluding remarks 
The role of CHEK2 in breast and colorectal cancer susceptibility in Finland was 
investigated. CHEK2 I157T was found to be a low-penetrance breast cancer 
susceptibility allele, conferring a 1.4-fold risk for carriers. Reduced or absent 
CHEK2 protein expression was observed in one-fifth of breast tumors from 
patients unselected for family history, implying that defective CHEK2 signaling 
contributes to tumorigenesis. Reduction in CHEK2 expression was more common 
in tumors with larger diameter and ER expression, but with regard to other tumor 
characteristics and prognosis of a patient no association was observed. The 
evaluation of CHEK2 1100delC tumors is complicated by the low frequency of the 
variant. Results from comparison of CHEK2 1100delC carrier tumors with 
noncarrier tumors were in line with the findings from the CHEK2 expression study. 
Tumors from CHEK2 1100delC carriers were more often of higher grade than 
tumors from noncarriers, and they also tended to be ER-positive more often, 
although generally 1100delC status does not seem to radically affect the tumor 
characteristics. 
 
Our results from a large set of CRC cases suggest that CHEK2 1100delC may not 
be a susceptibility allele for CRC, although a very small effect cannot be excluded. 
Furthermore, CHEK2 1100delC is equally frequent in HBCC phenotype families 
and in breast cancer families.  
 
Over 1000 CRC cases were screened for CHEK2 I157T, and a significantly higher 
frequency of I157T was observed among both familial and sporadic CRC cases. 
The relation of CHEK2 I157T with familial CRC has not been studied previously. 
CHEK2 I157T seems to be a susceptibility allele for both familial and sporadic 
CRC, conferring a 1.5-fold risk for carriers of this variant. CHEK2 I157T has been 
proposed to have a role as a multiple cancer susceptibility allele, which is 
supported by our results since we observed a higher frequency of the variant 







During the last five years CHEK2 has established its role as an important cancer 
susceptibility gene. It has become apparent that CHEK2 is a low-penetrance 
susceptibility gene for several cancer types, significantly contributing to familial 
cancer risk as well as to cancer risk at the population level. However, many 
challenges remain. Cellular processes are all about interactions and most 
certainly there are several other low-penetrance cancer susceptibility alleles and 
genes to be identified, and genes with a synergistic risk effect with CHEK2 
variants. Their identification is demanding since there are, as we have seen, 
differences in variant frequencies between populations, and the contribution to 
risk may also vary. While many pieces of the cancer puzzle have been identified, 
we still need to assemble the big picture, finding the interactions and how they are 
formed. This is the goal for the future, and I am humbled in being able to locate 
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